Propanal, 2-methyl-, phenylhydrazone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Propanal, 2-methyl-, phenylhydrazone
• 英文别名: N-[(E)-2-methylpropylideneamino]aniline
• 化学式: C₁₀H₁₄N₂
• mdl: MFCD01024489
• 分子量: 162.23
• InChiKey: JRPJYFGSRTYOBF-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Propanal, 2-methyl-, phenylhydrazone 生成 苯胺
  参考文献：
  名称：

  KUZNETSOV, M. A.;SUVOROV, A. A., ZH. ORGAN. XIMII, 1982, 18, N 9, 1923-1931

  摘要：

  DOI：
• 作为产物：
  描述：

  isobutylphenyldiimide 生成 Propanal, 2-methyl-, phenylhydrazone
  参考文献：
  名称：

  KUZNETSOV, M. A.;SUVOROV, A. A., ZH. ORGAN. XIMII, 1982, 18, N 9, 1923-1931

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS EN TANT QUE MODULATEURS DE LA SIGNALISATION TLR
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2020198368A1

  公开（公告）日：2020-10-01

  The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

  本发明公开涉及化合物、包含此类化合物的药物组合物，以及此类化合物在治疗炎症性疾病和与炎症信号传导过程相关的某些神经障碍的方法或药物中的用途，所述神经障碍包括但不限于错误折叠的蛋白质。
• [EN] COMPOUNDS AS MODULATORS OF TLR2 SIGNALING<br/>[FR] COMPOSÉS UTILISÉS EN TANT QUE MODULATEURS DE SIGNALISATION TLR2
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2019191189A1

  公开（公告）日：2019-10-03

  The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

  本公开涉及化合物、包含这种化合物的药物组合物，以及利用这些化合物进行治疗方法或用于治疗与炎症信号传导过程相关的炎症性疾病和某些神经系统疾病的药物。这些神经系统疾病与炎症信号传导过程有关，包括但不限于蛋白质错折。
• Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity
  申请人：Kume Masaharu

  公开号：US20090143414A1

  公开（公告）日：2009-06-04

  A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided. A compound represented by the general formula (I): wherein R X is a group represented by the formula: wherein R 1 is a hydrogen atom, optionally substituted alkyl, etc.; Z is —O—, —N(R 10 )—, etc.; R 10 is a hydrogen atom, alkyl, etc.; R 2 is a hydrogen atom, optionally substituted alkyl, etc.; R 18 is a hydrogen atom, optionally substituted alkyl, etc.; R 19 is optionally substituted alkyl, etc.; W 1 is an optionally substituted non-aromatic nitrogen-containing group; R 17 is a hydrogen atom, optionally substituted alkyl, etc.; R 3 and R 4 are independently a hydrogen atom, optionally substituted alkyl, etc.; X is —O—, —S—, or —N(R 12 )—, etc.; R 12 is a hydrogen atom, alkyl, etc.; and A is phenyl optionally having a substituent, etc., its pharmaceutically acceptable salt, or a solvate thereof.

  提供了一种抑制EGF受体酪氨酸激酶和HER2酪氨酸激酶的化合物。该化合物由通式（I）表示：其中RX是由以下式子表示的基团：其中R1是氢原子，可选取代烷基等；Z是—O—，—N（R10）—等；R10是氢原子，烷基等；R2是氢原子，可选取代烷基等；R18是氢原子，可选取代烷基等；R19是可选取代烷基等；W1是可选取代非芳香族含氮基团；R17是氢原子，可选取代烷基等；R3和R4分别是氢原子，可选取代烷基等；X是—O—，—S—或—N（R12）—等；R12是氢原子，烷基等；A是苯基，可选取代基等，其药物可接受的盐或其溶剂化合物。
• Method for the Preparation of 1-Acetyl-6-Amino-3,3-Dimethyl-2,3-Dihydroindole
  申请人：King Anthony

  公开号：US20120136163A1

  公开（公告）日：2012-05-31

  The present invention relates to processes for preparing indoline derivatives, particularly 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole.

  本发明涉及制备吲哚啉衍生物的过程，特别是1-乙酰基-6-氨基-3,3-二甲基-2,3-二氢吲哚的制备过程。
• SCHANTL, J. G.;HEBEISEN, P.;KARPELLUS, P., SYNTH. COMMUN., 19,(1989) N-2, C. 39-48
  作者：SCHANTL, J. G.、HEBEISEN, P.、KARPELLUS, P.

  DOI：——

  日期：——